BRPI0616452B8 - quinolinas e seu uso terapêutico - Google Patents

quinolinas e seu uso terapêutico

Info

Publication number
BRPI0616452B8
BRPI0616452B8 BRPI0616452A BRPI0616452A BRPI0616452B8 BR PI0616452 B8 BRPI0616452 B8 BR PI0616452B8 BR PI0616452 A BRPI0616452 A BR PI0616452A BR PI0616452 A BRPI0616452 A BR PI0616452A BR PI0616452 B8 BRPI0616452 B8 BR PI0616452B8
Authority
BR
Brazil
Prior art keywords
ring
region
solid state
seal
sealing material
Prior art date
Application number
BRPI0616452A
Other languages
English (en)
Inventor
Hynd George
Finch Harry
Gary Montana John
Colin Cramp Michael
Charles Ray Nicholas
Crackett Peter
Arienzo Rosa
Keith Harrison Trevor
Griffon Yann
Original Assignee
Argenta Discovery Ltd
Gb001 Inc
Pulmagen Therapeutics Asthma Ltd
Pulmagen Therapeutics Synergy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0519969.0A external-priority patent/GB0519969D0/en
Priority claimed from GB0610551A external-priority patent/GB0610551D0/en
Application filed by Argenta Discovery Ltd, Gb001 Inc, Pulmagen Therapeutics Asthma Ltd, Pulmagen Therapeutics Synergy filed Critical Argenta Discovery Ltd
Publication of BRPI0616452A2 publication Critical patent/BRPI0616452A2/pt
Publication of BRPI0616452B1 publication Critical patent/BRPI0616452B1/pt
Publication of BRPI0616452B8 publication Critical patent/BRPI0616452B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)

Abstract

método e dispositivo para a formação in situ de uma vedação em um anel em um poço. descreve-se um método e um dispositivo para a formação in situ de uma vedação (17) em uma região (2) de um anel (16) localizado em torno de uma estrutura de tubulação (4) em um poço (18), em que o método compreende as seguintes etapas: (a) levar um dispositivo de perfuração ao interior da estrutura de tubulação (4) até um local vis-á-vis tal região (2) do anel (16); (b) por meio do dispositivo de perfuração, efetuar pelo menos um orifício de parede de tubulação (13) da estrutura de tubulação (4) na região (2) do anel; (c) forçar um material de vedação líquido, o qual é capaz de passar ao estado sólido, através do orifício (13) e ao interior da região do anel (2) para o preenchimento da mesma, quando então o material de vedação passa ao estado sólido e forma a vedação (17). a característica distintiva do método consiste de que a etapa (c) do mesmo compreende acionalmente: escolher um material obturador fusível em estado sólido (5) como matéria prima para o material de vedação; aquecer e fundir pelo menos uma parte do material obturador (5) de estado sólido; e subsequentemente forçar o material obturador líquido (5) para o interior da região de anel (2) através do pelo menos um orifício de parede de tubulação (13), quando então o material obturador líquido (5) passa ao estado sólido e forma a vedação (17) na região de anel (2).
BRPI0616452A 2005-09-30 2006-09-29 quinolinas e seu uso terapêutico BRPI0616452B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0519969.0 2005-09-30
GBGB0519969.0A GB0519969D0 (en) 2005-09-30 2005-09-30 Quinoline compounds
GB0610551A GB0610551D0 (en) 2006-05-26 2006-05-26 Quinoline compounds
GB0610551.4 2006-05-26
PCT/GB2006/003644 WO2007036743A2 (en) 2005-09-30 2006-09-29 Quinolines and their therapeutic use

Publications (3)

Publication Number Publication Date
BRPI0616452A2 BRPI0616452A2 (pt) 2011-06-21
BRPI0616452B1 BRPI0616452B1 (pt) 2020-10-13
BRPI0616452B8 true BRPI0616452B8 (pt) 2021-05-25

Family

ID=37579213

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0616452A BRPI0616452B8 (pt) 2005-09-30 2006-09-29 quinolinas e seu uso terapêutico

Country Status (17)

Country Link
US (1) US7858640B2 (pt)
EP (1) EP1928457B1 (pt)
JP (1) JP4990285B2 (pt)
AU (1) AU2006296397B2 (pt)
BR (1) BRPI0616452B8 (pt)
CA (1) CA2622000C (pt)
DK (1) DK1928457T3 (pt)
EA (1) EA015358B1 (pt)
ES (1) ES2399061T3 (pt)
HK (1) HK1124784A1 (pt)
IL (1) IL190055A (pt)
NO (1) NO343189B1 (pt)
NZ (1) NZ566537A (pt)
PL (1) PL1928457T3 (pt)
PT (1) PT1928457E (pt)
SI (1) SI1928457T1 (pt)
WO (1) WO2007036743A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200802417A1 (ru) * 2006-06-09 2009-06-30 Икос Корпорейшн Замещенные фенилуксусные кислоты как dp-2-антагонисты
JP5280357B2 (ja) 2006-07-07 2013-09-04 スティーブン・ピー・ガベック Ｐｄｅ４の二環式ヘテロアリール阻害剤
US8138205B2 (en) 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
WO2008119917A1 (en) * 2007-03-29 2008-10-09 Argenta Discovery Limited Quinoline derivatives as crth2 receptor ligands
DK2139881T3 (da) * 2007-04-04 2012-01-30 Pulmagen Therapeutics Asthma Ltd Quinoliner og deres terapeutiske anvendelse
GB0722055D0 (en) * 2007-11-09 2007-12-19 Argenta Discovery Ltd Compounds
CA2707785C (en) 2007-12-14 2015-11-03 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
GB0818365D0 (en) * 2008-10-07 2008-11-12 Argenta Discovery Ltd Quinoline compounds
GB0818366D0 (en) * 2008-10-07 2008-11-12 Argenta Discovery Ltd Quinolin-2-one-compounds
US8188090B2 (en) * 2008-11-17 2012-05-29 Hoffman-La Roche Inc. Naphthylacetic acids
KR101920090B1 (ko) 2010-07-05 2018-11-19 이도르시아 파마슈티컬스 리미티드 1-페닐-치환된 헤테로시클릴 유도체 및 프로스타글란딘 ｄ２ 수용체 조절자로서 이의 용도
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EA026456B1 (ru) 2011-12-16 2017-04-28 Атопикс Терапьютикс Лимитед Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита
CA2858328A1 (en) 2011-12-21 2013-06-27 Actelion Pharmaceuticals Ltd Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
CN104428305A (zh) 2012-07-05 2015-03-18 埃科特莱茵药品有限公司 1-苯基-取代的杂环衍生物及其作为前列腺素d2受体调节剂的用途
AR106515A1 (es) * 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
CA3228632A1 (en) 2015-12-24 2017-06-29 Kyowa Kirin Co., Ltd. .alpha.,.beta.-unsaturated amide compound
KR20190018643A (ko) * 2016-05-16 2019-02-25 풀마젠 테라퓨틱스 (애즈마) 리미티드 퀴놀린 유도체의 결정
KR20200019979A (ko) 2017-06-23 2020-02-25 쿄와 기린 가부시키가이샤 α, β 불포화 아미드 화합물
WO2020172380A1 (en) 2019-02-22 2020-08-27 Gb001, Inc. Treatment of asthma patients having high baseline feno levels
US20200354374A1 (en) * 2019-05-06 2020-11-12 Inspira, LLC Chemical Entities, Pharmaceutical Formulations, and Methods for Treating Fibrosis
WO2020227570A1 (en) 2019-05-08 2020-11-12 Gb001, Inc. Methods of treating chronic rhinosinusitis with pexopiprant

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58225065A (ja) * 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd ２−キノロン誘導体
TW297025B (pt) * 1992-02-14 1997-02-01 Squibb & Sons Inc
MXPA03007765A (es) * 2001-03-01 2003-12-08 Shionogi & Co Compuestos heteroarilo que contienen nitrogeno, que tienen actividad inhibitoria contra virus de inmunodeficiencia humana integrasa.
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
US7358249B2 (en) * 2002-08-13 2008-04-15 Shionogi & Co., Ltd. Heterocyclic compounds having inhibitory activity against HIV integrase
EP1556047A4 (en) * 2002-10-04 2009-09-30 Millennium Pharm Inc ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP1413306A1 (en) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
EP1758579A1 (en) * 2004-05-29 2007-03-07 7TM Pharma A/S Crth2 receptor ligands for medicinal uses
UY29223A1 (es) * 2004-11-23 2006-06-30 Astrazeneca Ab Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación

Also Published As

Publication number Publication date
IL190055A0 (en) 2008-08-07
HK1124784A1 (en) 2009-07-24
ES2399061T3 (es) 2013-03-25
WO2007036743A2 (en) 2007-04-05
IL190055A (en) 2015-07-30
NO20081327L (no) 2008-06-19
SI1928457T1 (sl) 2013-06-28
PT1928457E (pt) 2013-02-19
PL1928457T3 (pl) 2013-04-30
US7858640B2 (en) 2010-12-28
JP2009510045A (ja) 2009-03-12
CA2622000C (en) 2014-01-21
DK1928457T3 (da) 2013-02-04
WO2007036743A3 (en) 2007-09-20
EA200800640A1 (ru) 2008-10-30
BRPI0616452B1 (pt) 2020-10-13
EP1928457B1 (en) 2012-12-12
CA2622000A1 (en) 2007-04-05
NZ566537A (en) 2010-10-29
EP1928457A2 (en) 2008-06-11
EA015358B1 (ru) 2011-06-30
NO343189B1 (no) 2018-11-26
AU2006296397B2 (en) 2011-12-15
BRPI0616452A2 (pt) 2011-06-21
AU2006296397A1 (en) 2007-04-05
JP4990285B2 (ja) 2012-08-01
US20090156600A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
BRPI0616452B8 (pt) quinolinas e seu uso terapêutico
BRPI0607629A2 (pt) método e dispositivo para a formação in situ de uma vedação em um anel em um poço
BR112018014080A2 (pt) receptor de cartucho, sistema de cartucho, máquina de preparação de bebida e processo para produção de uma bebida
BR112015017294A2 (pt) método para tratar uma zona de perda de fluido em um furo de poço em uma formação subterrânea
BR112013013146A2 (pt) obturador para empacotamento de cascalho em canal de fluxo alternativo e método para completamento de um poço
MY178594A (en) Barrier testing method
BRPI0814733A2 (pt) método para melhorar a produção a partir de uma formação subterrânea, e, sistema de poço.
MY163721A (en) An active external casing packer (ecp) for frac operations in oil and gas wells
BR112018001740A2 (pt) sistema de conclusão de fundo de poço vedando contra camada de cobertura
WO2014060293A3 (en) Sealing apparatus and method
BR112018075798A2 (pt) gaxeta de furo de poço, sistema de poço, e, método de operações de perfuração.
BRPI0819747A2 (pt) Aparelho para enchimento com cascalho de um poço subterrâneo aberto, método para enchimento com cascalho de um poço usando uma suspensão de cascalho, método para criar intencionalmente um tampão de cascalho no espaço anular entre uma peneira de areia e um poço aberto em uma região de fundo de poço, e método para enchimento com cascalho de um poço.
MY184722A (en) Electronic rupture discs for interventionless barrier plug
MX345360B (es) Una barrera anular con un dispositivo de detección de expansión.
BR112015018983A2 (pt) aparelho para teste e amostragem de formação de fundo de poço, e, método para testar e amostrar um fluido de formação
GB2546646A (en) Methods for mitigating annular pressure build up in a wellbore using materials having a negative coefficient of thermal expansion
BR112013020760A2 (pt) junta de deslocamento, e, método para espaçamento de tubulares em um furo de poço
BR112015000876A2 (pt) aparelho e método para isolar uma primeira zona de uma segunda zona em um furo de poço subterrâneo
BR112019002009A2 (pt) sistema, aparelho, método, cápsula e kit de cápsulas para preparar uma bebida.
MX2010009988A (es) Fluidos aislantes de base acuosa mejorados y metodos relacionados.
AR114170A1 (es) Camisas de fracturamiento de desplazamiento automático
MX342048B (es) Una barrera anular con un dispositivo autoactivado.
WO2009149458A8 (en) Compression sealing apparatus and method for use of the same
CO2020000232A2 (es) Nanopartículas de sílice fluorescentes y multicolores como trazadores para la producción y monitoreo de pozos
WO2009126413A3 (en) Sealing between alignable windows for lateral wellbore drilling

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB)

Free format text: NOME ALTERADO DE: ARGENTA DISCOVERY LIMITED

B25A Requested transfer of rights approved

Owner name: PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB)

Free format text: TRANSFERIDO DE: PULMAGEN THERAPEUTICS (SYNERGY) LIMITED

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: GB001, INC (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/09/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2690 DE 26-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.